ID   NCI-H3122-CHR-A1
AC   CVCL_4Y37
SY   H3122-CHR-A1; H3122 CHR-A1
DR   Cosmic; 2245572
DR   Wikidata; Q54872052
RX   PubMed=25228534;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:62268; Alectinib (CH5424802; RO5424802; AF-802).
CC   Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5160 ! NCI-H3122
SX   Male
AG   54Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 8
//
RX   PubMed=25228534; DOI=10.1158/1078-0432.CCR-14-1511;
RA   Katayama R., Friboulet L., Koike S., Lockerman E.L., Khan T.M.,
RA   Gainor J.F., Iafrate A.J., Takeuchi K., Taiji M., Okuno Y., Fujita N.,
RA   Engelman J.A., Shaw A.T.;
RT   "Two novel ALK mutations mediate acquired resistance to the
RT   next-generation ALK inhibitor alectinib.";
RL   Clin. Cancer Res. 20:5686-5696(2014).
//